Milan, Italy: Researchers have developed a genetic test that can identify how patients with triple negative early-stage breast cancer will respond to immunotherapy drugs. This means that patients who are unlikely to respond to these drugs can avoid the adverse side effects associated with them and can be treated with...
Latest News
San Francisco, Calif. – In a discovery that could hasten treatment for patients with multiple sclerosis (MS), UC San Francisco scientists have discovered a harbinger in the blood of some people who later went on to develop the disease. In about 1 in 10 cases of MS, the body begins...
San Francisco, Calif. – Combining testosterone-blocking drugs in patients with prostate cancer relapse prevents the spread of cancer better than treatment with a single drug, a multi-institution, Phase 3 clinical trial led by UC San Francisco researchers has found. The approach can extend the time between debilitating drug treatments without...
Santa Barbara, Calif. — UC Santa Barbara researchers and collaborators in Colombia, Brazil and Germany are progressing toward an understanding of mechanisms that underlie Alzheimer’s disease, in particular an early-onset, genetic form that has afflicted generations of an extended family in Colombia. They also shed some light on a woman...
Dapirolizumab pegol (DZP) showed efficacy across multiple clinical endpoints in the PHOENYCS GO study, including fatigue and measures of disease activity DZP showed consistent improvements in fatigue, a common and debilitating symptom of systemic lupus erythematosus (SLE) At Week 48, more individuals receiving DZP experienced no or low disease activity...
ATLANTA, GA — UCB, a global biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental Biologics License Application (sBLA) for BIMZELX® (bimekizumab-bkzx), an IL-17A and IL-17F inhibitor, for the treatment of adults with moderate-to-severe hidradenitis suppurativa (HS). In addition, a second sBLA...
ATLANTA, Georgia — UCB, a global biopharmaceutical company, today presented positive efficacy and safety results from the GEMZ phase 3 study investigating adjunctive fenfluramine (FFA) in children and adults with CDKL5 deficiency disorder (CDD) at the American Epilepsy Society (AES) meeting in Atlanta, December 5-9, 2025.1 The trial met its primary endpoint and...
ATLANTA — UCB (Euronext Brussels: UCB), a global biopharmaceutical company, today announced that it will be presenting results from across its portfolio in generalized myasthenia gravis (gMG) at the American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) annual meeting and the Myasthenia Gravis Association of America Scientific Session taking place...
ATLANTA — UCB, a global biopharmaceutical company, today announced that it will present six abstracts in hidradenitis suppurativa (HS) at the 8th Annual Symposium on Hidradenitis Suppurativa Advances (SHSA) in Phoenix, Arizona. Data and analyses in HS will be presented across two oral presentations and four posters. “The data to...
ATLANTA, Georgia — UCB, a global biopharmaceutical company, today announced that the final analysis of an open-label extension (OLE) study with the objective to describe long-term safety and effectiveness of FINTEPLA (fenfluramine) in Lennox-Gastaut syndrome (LGS) was published in Epilepsy & Behavior.2 No new or unexpected treatment-emergent adverse events (TEAEs) were reported.2 Children and adults...